Sigma receptor ligands: Possible application as therapeutic drugs and as radiopharmaceuticals

Current Pharmaceutical Design

Volumn 12, Issue 30, 2006, Pages 3857-3876

  Hashimoto, Kenji ^a   Ishiwata, Kiichi ^b  

^a CHIBA UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

Author keywords

4 phenyl 1 (4 phenylbutyl) piperidine (PPBP); Antidepressants; CNS; Cocaine addiction; Ischemia; NMDA receptor

Indexed keywords

1 CYCLOPROPYLMETHYL 4 [2 (4 FLUOROPHENYL) 2 OXOETHYL]PIPERIDINE; 2 [4 METHOXY 3 (2 PHENYLETHOXY)PHENYL] N,N DIPROPYLETHYLAMINE; ALPHA (4 FLUOROPHENYL) 4 (5 FLUORO 2 PYRIMIDINYL) 1 PIPERAZINEBUTANOL; AMPHETAMINE; CALCIUM ION; CITALOPRAM; ELIPRODIL; FLUORODEOXYGLUCOSE F 18; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; N ALLYLNORMETAZOCINE; NEUROLEPTIC AGENT; OPIATE AGONIST; OPIATE ANTAGONIST; PAROXETINE; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT; RECEPTOR SUBTYPE; RIMCAZOLE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SIGMA 1 OPIATE RECEPTOR; SIGMA 2 OPIATE RECEPTOR AGONIST; SIGMA RECEPTOR LIGAND; SM 21; SPHINGOLIPID; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; BRAIN ISCHEMIA; CALCIUM CELL LEVEL; CANCER INHIBITION; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COCAINE DEPENDENCE; COGNITIVE DEFECT; DEPRESSION; DRUG BINDING SITE; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; HUMAN; IMAGING SYSTEM; MALIGNANT NEOPLASTIC DISEASE; NEUROPATHOLOGY; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SCHIZOPHRENIA; STRUCTURE ANALYSIS; TISSUE DISTRIBUTION; TUMOR CELL;

ANIMALS; ANTIPSYCHOTIC AGENTS; HUMANS; LIGANDS; MENTAL DISORDERS; RADIOPHARMACEUTICALS; RECEPTORS, SIGMA;

EID: 33749852123     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206778559614     Document Type: Review

References (195)

1. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 1976; 197: 517-32.
2. 3H]SKF-10047 to etorphine-inaccessible sites in guinea-pig brain. J Pharmacol Exp Ther 1982; 223: 284-90.
3. Su TP. Delineating biochemical and functional properties of sigma receptors: emerging concepts. Crit Rev Neurobiol 1993; 7: 187-203.
4. Maurice T, Urani A, Phan VL, Romieu P. The interaction between neuroactive steroids and the sigmal receptor function: behavioral consequences and therapeutic opportunities. Brain Res Brain Res Rev 2001; 37: 116-32.
5. Su TP, Hayashi T. Understanding the molecular mechanism of sigma-1 receptors: towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal trairsduction. Curr Med Chem 2003; 10: 2073-80.
6. Hayashi T, Su TP. Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders. CNS Drugs 2004; 18: 269-84.
7. Takebayashi M, Hayashi T, Su TP. A perspective on the new mechanism of antidepressants: neuritogenesis through sigma-1 receptors. Pharmacopsychiatry 2004; 37(Suppl 3): S208-13.
8. Guitart X, Codonym X, Monroy X. Sigma receptors: biology and therapeutic potential. Psychopharmacology 2004; 174: 301-19.
9. Su TP, London ED, Jaffe JH. Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems. Science 1988; 240: 219-21.
10. Bowen WD, Hellewell SB, McGarry KA. Evidence for a multi-site model of the rat brain sigma receptor. Eur J Pharmacol 1989; 163: 309-18.
11. Hellewell SB, Bowen WD. A sigma-like binding site in rat pheochromocytoma (PC12) cells: decreased affinity for (+)-benzomorphans and lower molecular weight suggest a different sigma receptor form from that of guinea pig brain. Brain Res 1990; 527: 244-53.
12. Quirion R, Bowen WD, Itzhak Y, Junien L, Musacchio JM, Rothman RB, et al. A proposal for the classification of sigma binding sites. Trends Pharmacol Sci 1992; 13: 85-6.
13. Walker JM, Bowen WD, Walker FO, Matsumoto RR, De Costa B, Rice KC. Sigma receptors: biology and function. Pharmacol Rev 1990; 42: 355-402.
14. 3H]tolyl) guanidine with sigma 2 binding sites in rat heart membrane preparations. Eur J Pharmacol 1991; 209: 245-8.
15. 2 receptors: characterization by ligand binding and photoaffinity labeling. Eur J Pharmacol 1994; 268: 9-18.
16. Wolfe SA Jr, Culp SG, De Souza EB. Sigma-receptors in endocrine organs: identification, characterization, and autoradiographic localization in rat pituitary, adrenal, testis, and ovary. Endocrinology 1989; 124: 1160-72.
17. Hanner M, Moebius FF, Flandorfer A, Knaus HG, Striessnig J, Kempner E, et al. Purification, molecular cloning, and expression of the mammalian sigmal-binding site. Proc Natl Acad Sci USA 1996; 93: 8072-7.
18. Seth P, Leibach FH, Ganapathy V. Cloning and structunal analysis of the cDNA and the gene encoding the murine type 1 sigma receptor. Biochem Biophys Res Commun 1997, 241: 535-40.
19. Seth P, Fei YJ, Li HW, Huang W, Leibach FH, Ganapatby V. Cloning and functional characterization of a sigma receptor from rat brain. J Neurochem 1998, 70: 922-31.
20. Kekuda R, Prasad PD, Fei YJ, Leibach FH, Ganapathy V. Cloning and functional expression of the human type 1 sigma receptor (hSigmaR1). Biochem Biophys Res Commun 1996; 229: 553-8.
21. 2+, concentration. J Pharmacol Exp Ther 2000; 293: 788-98.
22. Hayashi T, Su TP. Regulating ankyrin dynamics: Roles of sigma-1 receptors. Proc Natl Acad Sci USA 2001; 98: 491-6.
23. Langa F, Codony X, Tovar V, Lavado A, Gimenez E, Cozar P, et al. Generation and phenotypic analysis of sigma receptor type I (sigma 1) knockout mice. Eur J Neurosci 2003: 18: 2188-96.
24. Junien JL, Leonard BE. Drugs acting on sigma and phencyclidine receptors: A review of their nature, function and possible therapeutic importance. Clin Neuropharmcol 1989; 12: 353-74.
25. Jansen KLR, Faull RLM, Storey P, Leslie RA. Loss of sigma binding sites in the CA1 area of the anterior hippocampus in Alzheimer's disease correlates with CA1 pyramidal cell loss. Brain Res 1993; 623: 299-302.
26. Weissman AD, Casanova MF, Kleinman JE, London ED, de Souza EB. Selective loss of cerebral cortical sigma, but not PCP binding sites in schizophrenia. Biol Psychiatry 1992; 29: 41-54.
27. 4 sites in schizophrenic brains. Eur J Pharmacol 1996; 314: R34.
28. Thomas GE, Szucs M, Mamone JY, Bem WT, Rush MD, Johnson FE, et al. Sigma and opioid receptors in human brain tumors. Life Sci 1990; 46: 1279-86.
29. Bem WT, Thomas GE, Mamone Y, Homan SM, Levy BK, Johnson FE, et al. Overexpression of receptors in nonneural human tumors. Cancer Res 1991; 51, 6558-62.
30. Vilner BJ, John CS, Bowen WD. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res 1995; 55: 408-13.
31. Mach RH, Smith CR, al-Nabulsi I, Whirrett BF, Childers SR, Wheeler KT. Sigma 2 receptors as potential biomarkers of proliferation in breast cancer. Cancer Res 1997; 57: 156-61.
32. Al-Nabulsi I, Mach RH, Wang LM, Wallen CA, Keng PC, Sten K, et al. Effect of ploidy, recruitment enviromnental factors, and tamoxifen treatment on the expression of sigma-2 receptors in proliferating and quiescent tumour cells. Br J Cancer 1999; 91: 925-33.
33. Wheeler KT, Wang LM, Wallen CA, Childers SR, Cline JM, Keng PC, et al. Sigma-2 receptors as a biomarker of proliferation in solid tumours. Br J Cancer 2000; 82: 1223-32.
34. Gillgan PJ, Tam SW. Sigma receptor ligands: potential drugs for the treatment of CNS disorders? Drug News Perspect 1994; 7: 13-8.
35. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148: 1301-8.
36. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995, 52: 998-1007.
37. Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry 1996; 3: 241-53.
38. Hashimoto K, Okamura N, Shimizu E, Iyo M. Glutamate hypothesis of schizophrenia and approach for possible therapeutic drugs. Curr Med Chem CNS Agents 2004; 4: 147-54.
39. Hashimoto K, Shimizu E, Iyo M. Dysfunction of glia-neuron communication in pathophysiology of schizophrenia. Curr Psychiatry Rev 2005; 1: 151-63,
40. Okuyama S, Nakazato A. NE-100: a novel sigma receptor antagonist CNS Drug Rev 1996; 2: 226-37.
41. Borison RL, Diamond BI, Dren AT. Does sigma receptor antagonism predict clinical antipsychotic efficacy? Psychopharmacol Bull 1991; 27: 103 -6.
42. Gewirtz; GR, Gorman JM, Volavka J, Macaluso J, Gribkoff G, Taylor DP, et al. BMY 14802, a sigma receptor ligand for the treatment of schizophrenia. Neuropsychopharmacology 1994; 10: 37-40.
43. Modell S, Naber D, Holzbach R. Efficacy and safety of an opiate sigma-receptor antagonist (SL 82.0715) in schizophrenic patients with negative symptoms: an open dose-range study. Pharmacopsychiatry 1996; 9: 63-6.
44. 2 receptor subtypes. Neuroscience 1997; 76: 467-77.
45. Matsumoto RR, Hemstreet MK, Lai NL, Thurkauf A, De Costa BR, Rice KC, el al. Drug specificity of pharmacological dystonia. Pharmacol Biochem Behav 1990; 36: 151-5.
46. Matsumoto RR, Bowen WD, Tom MA, Vo VN, Truong DD, De Costa BR. Characterization of two novel sigma receptor ligands: antidystonic effects in rats suggest sigma receptor antagonism. Eur J Pharmacol 1995; 280: 301-10.
47. Tran TT, de Costa BR, Matsumoto RR. Microinjection of sigma ligands into cranial nerve nuclei produces vacuous chewing in rats. Psychopharmacology (Berl) 1998; 137: 191-200.
48. Walker JM, Bowen WD, Patrick SL, Williams WE, Mascarella SW, Bai X, et al. A comparison of (-)-deoxybenzomorphans devoid of opiate activity with their dextrorotatory phenolic counterparts suggests role of sigma 2 receptors in motor function. Eur J Pharmacol 1993; 231: 61-8.
49. Mach RH, Wu L, West T, Whirrett BF, Childers SR. The analgesic tropane analogue (+/-)-SM 21 has a high affinity for sigma2 receptors. Life Sci 1999; 64: PL131-7.
50. 2 antagonist. Pharmacol Biochem Behav 2000; 67: 659-62.
51. Narita N, Hashimoto Y, Tomitaka S, Minabe Y. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol 1996; 307: 117-9.
52. 3H] 1,3-di-o-tolyl-guanidine-defined sigma binding sites by desipramine, propranolol and alprenolol in rat brain. Eur J Pharmacol 1997 331: 319-23.
53. Sanchez C, Meier E. Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? Psychopharmacology (Berl) 1997; 129: 197-205.
54. Matsuno K, Kobayashi T, Tanaka MK, Mita S. Sigma 1 receptor subtype is involved in the relief of behavioral despair in the mouse forced swimming test. Eur J Phamacol 1996; 312: 267-71.
55. Ukai M, Maeda H, Nanya Y, Kameyama T, Matsuno K. Beneficial effects of acute and repeated administrations of sigma receptor agonists on behavioral despair in mice exposed to tail suspension. Pharmacol Biochem Behav 1998; 61: 247-52.
56. Urani A, Roman FJ, Phan VL, Su TP, Maurice T. The antidepressant-like effect induced by sigma-1 receptor agonists and neuroactive steroids in mice submitted to the forced swimming test. J Pharmacol Exp Ther 2001; 298: 1269-79.
57. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron 2002; 34: 13-25.
58. Nestler EJ, Gould E, Manji H, Buncan M, Duman RS, Greshenfeld HK, et al. Preclinical models: status of basic research in depression. Biol Psychiatry 2002; 52: 503-28.
59. Takebayashi M, Hayashi T, Su. TP. Nerve growth factor-induced neurite sprouting in PC12 cells involves sigma-1 receptors: implications for antidepressants. J Pharmacol Exp Ther 2002; 303: 1227-37.
60. Maurice T, Lockhart BP. Neuroprotective and anti-amnesic potentials of sigma receptor ligands. Prog Neuropsychopharmacol Biol Psychiatry 1997; 21: 69-102.
61. Lobner D, Lipton P. Sigma-ligands and non-competitive NMDA antagonists inhibit glutamate release during cerebral ischemia. Neurosci Lett 1990; 117: 169-74.
62. Lesage AS, De Loore KL, Peeters L, Leysen E. Neuroprotective sigma ligands interfere with the glutamate-activated NOS pathway in hippocampal cell culture. Synapse 1995; 20:156-64.
63. O'Neill M, Caldwell M, Earley B, Canney M, O'Halloran A, Kelly J, et al. The sigma receptor ligand JO 1784 (igmesine hydrochloride) is neuroprotective in the gerbil model of global cerebral ischaemia. Eur J Pharmacol 1995; 283: 217-25.
64. Gotti B, Duverger D, Bertin J, Carter C, Dupont R, Frost J, et al. Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. I. Evidence for efficacy in models of focal cerebral ischemia. J Pharmacol Exp Ther 1988; 247: 1211-21.
65. Carter C, Benavides J, Legendre P, Vincent JD, Noel F, Thuret F, et al. Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. II. Evidence for N-methyl-D-aspartate receptor antagonist properties. J Pharmacol Exp Ther 1988; 247: 1222-32.
66. 3H]ifenprodil binding to sigma receptors in rat brain. Eur J Pharmacol 1993; 236: 159-63.
67. 3H]ifenprodil binding in rat brain. Eur J Pharmacol 1994; 266: 67-77.
68. Hashimoto K, London ED. Interactions of erythro-ifenprodil, threo-ifenprodil, erythro-iodoifenprodil, and eliprodil with subtypes of sigma receptors. Eur J Pharmacol 1995; 273: 307-10.
69. 3H]4-phenyl-1-(4-phenylbutyl)piperidine. Synapse 1995; 20: 85-90.
70. Takahashi H, Kirsch JR, Hashimoto K, London ED, Koehler RC, Traystman RJ. PPBP [4-phenyl-1-(4-phenylbutyl) piperidine] decreases brain injury after transient focal ischemia in rats. Stroke 1996; 27: 2120-3.
71. Takahashi H, Kirsch JR, Hashimoto K, London ED, Koehler RC, Traystman RJ. PPBP [4-phenyl-1-(4-phenylbutyl) piperidine], a potent sigma-receptor ligand, decreases brain injury after transient focal ischemia in cats. Stroke 1995; 26: 1676-82.
72. Takahashi H, Traystman RJ, Hashimoto Y, London ED, Kirsch JR. Postischemic brain injury is affected stereospecifically by pentazocine in rats. Anesth Analg 1997; 85: 353-7.
73. Hanikuni I, Bhardwaj A, Traystman RJ, Crain B, London ED, Kirsch JR. Neuroprotection from focal ischemia by 4-phenyl-1-(4phenylbutyl) piperidine (PPBP) is dependent on treatment duration in rats. Anesth Analg 1998; 87: 1299-305.
74. Harukini I, Bhardwaj A, Shaivitz AB, DeVries AC, London ED, Hum PD, et al. sigma-1 receptor ligand 4-phenyl-1-(4-phenylbutyl)-piperidine affords neuroprotection from focal ischemia with prolonged reperfusion. Stroke 2000; 31: 976-82.
75. Bhardwaj A, Sawada. M, London ED, Koehler RC, Traystman RJ, Kirsch JR. Potent sigma-1 receptor ligand 4-phenyl-1-(4phenylbutyl) piperidine modulates basal and N-methyl-D-aspartate-evoked nitric oxide production in vivo. Stroke 1998; 29. 2404-10.
76. 1-receptor ligand 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP) is linked to reduced neuronal nitric oxide production. Stroke 2001; 32: 1613-20.
77. Matsuno K, Mita S. SA4503: a novel sigma, receptor agonist. CNS Drug Rev 1998; 4: 1-24.
78. Earley B, Burke M, Leonard BE, Gouret CJ, Junien JL. Evidence for an anti-amnesic effect of JO 1784 in the rat: a potent and selective ligand for the sigma receptor, Brain Res 1991; 546: 282-6.
79. Matsuno K, Senda T, Matsunaga K, Mita S. Ameliorating effects of sigma receptor ligands on the impairment of passive avoidance tasks in mice: involvement in the central acetylcholinergic system. Eur J Pharmacol 1994; 261: 43-51.
80. Kobayashi T, Matsuno K, Mita S. Regional differences of the effect of sigma receptor ligands on the acetylcholine release in the rat brain. J Neural Transm 1996; 103: 661-9.
81. Kobayashi T, Matsuno K, Nakata K, Mita S. Enhancement of acetylcholine release by SA4503, a novel sigma 1 receptor agonist, in the rat brain. J Pharmacol Exp Ther 1996, 279: 106-13.
82. Maurice T, Su TP, Parish DW, Nabeshima T, Privat A. PRE-084, a sigma selective PCP derivative, attenuates MK-801-induced impairment of learning in mice. Pharmacol Biochem Behav 1994; 49: 859-69.
83. Zou LB, Yamada K, Nabeshima T. Sigma receptor ligands (+)-SKF10,047 and SA4503 improve dizocilpine-induced spatial memory deficits in rats. Eur J Pharmacol 1998; 355: 1-10.
84. Zou LB, Yamada K, Sasa M, Nakata Y, Nabeshima T. Effects of sigma-1 receptor agonist SA4503 and neuroactive steroids on performance in a radial arm maze task in rats. Neuropharmacology 2000; 39: 1617-27.
85. Maurice T. Beneficial effect of the sigma-1 receptor agonist PRE-084 against the spatial learning deficits in aged rats. Eur J Pharmacol 2001; 431: 223-7.
86. Meunier J, Gue M, Recasens M, Maurice T. Attenuation by a sigma-1 receptor agonist of the learning and memory deficits induced by a prenatal restraint stress in juvenile rats. Br J Pharmacol 2004; 142: 689-700.
87. Nestler EJ. Molecular mechanisms of opiate and cocaine addiction. Curr Opin Neurobiol 1997; 7: 713-9.
88. Nestler EJ. Historical review: Molecular and cellular mechanisms of opiate and cocaine addiction. Trends Pharmacol Sci 2004; 25: 210-8.
89. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 1987; 237: 1219-23.
90. Kuhar MJ, Ritz MC, Boja JW. The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci 1991, 14: 299-302.
91. Sharkey J, Glen KA, Wolfe S, Kuhar MJ. Cocaine binding at sigma receptors. Eur J Pharmacol 1988; 149: 171-4.
92. Ritz MC, George FR. Cocaine-induced seizures and lethality appear to be associated with distinct central nervous system binding sites. J Pharmacol Exp Ther 1993; 264: 1333-43.
93. Matsumoto RR, McCracken KA, Friedman MJ, Pouw B, De Costa BR, Bowen WD. Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting sigma-1 receptors produce anti-cocaine effects in mice. Eur J Pharmacol 2001; 419: 163-74.
94. Su TP, Hayashi T. Cocaine affects the dynamics of cytoskeletal proteins via sigma-1 receptors. Trends Pharmacol Sci 2001; 22: 456-8.
95. Maurice T, Martin-Fardon R, Romieu P, Matsumoto RR, Sigma-1 receptor antagonists represent a new strategy against cocaine addiction and toxicity. Neurosci Biobehav Rev 2002; 26: 499-527.
96. Matsumoto RR, Liu Y, Lerner M, Howard EW, Brackett DJ. Sigma receptors: potential medications development target for anticocaine agents. Eur J Pharmacol 2003; 469: 1-12.
97. Menkel M, Terry P, Pontecorvo M, Katz JL, Witkin JM. Selective sigma ligands block stimulant effects of cocaine. Eur J Pharmacol 1991; 201: 251-2.
98. Romieu P, Martin-Fardon R, Maurice T. Involvement of the sigma1 receptor in the cocaine-induced conditioned place preference. Neuroreport 2000; 11: 2885-8.
99. Romieu P, Phan VL, Martin-Fardon R, Maurice T. Involvement of the sigma-1 receptor in cocaine-induced conditioned place preference: possible dependence on dopamine uptake blockade. Neuropsychopharmacology 2002; 26: 444-55.
100. Pascual-Leone A, Dhuna A, Altafullah I, Anderson DC. Cocaine-induced seizures. Neurology 1990; 40: 404-7.
101. Matsumoto RR, McCracken KA, Pouw B, Miller J, Bowen WD, Williams W, et al. N-alkyl substituted analogs of the sigma receptor ligand BD1008 and traditional sigma receptor ligands affect cocaine-induced convulsions and lethality in mice. Eur J Pharmacol 2001; 411: 261-73.
102. Matsumoto RR, McCracken KA, Pouw B, Zhang Y, Bowen WD. Involvement of sigma receptors in the behavioral effects of cocaine: evidence from novel ligands and antisense oligodeoxynucleotides. Neuropharmacology 2002, 42: 1043-55.
103. Witkin JM, Terry P, Menkel M, Hickey P, Pontecorvo M, Ferkany J, et al. Effects of the selective sigma receptor ligand, 6-[6-(4-hydroxypiperidinyl)hexyloxy]-3-methylflavone (NPC 16377), on behavioral and toxic effects of cocaine. J Pharmacol Exp Ther 1993; 266: 473-82.
104. Ujike H, Kuroda S, Otsuki S. Sigma receptor antagonists block the development of sensitization to cocaine. Eur J Pharmacol 1996; 296: 123-8.
105. John CS, Bowen WD, Varma VM, McAfee JG, Moody TW. Sigma receptors are expressed in human non-small cell lung carcinoma. Life Sci 1995; 56: 2385-92.
106. Moody TW, Leyton J, John C. Sigma ligands inhibit the growth of small cell lung cancer cells. Life Sci 2000; 66: 1979-86.
107. 123I-iodo-4-methoxybenzamide of patients with suspected primary breast cancer: first clinical results. J Nucl Med 2002; 43: 1647-9.
108. Aydar E, Palmer CP, Djamgoz MB. Sigma receptors and cancer: possible involvement of ion channels. Cancer Res 2004; 64: 5029-35.
109. Zhu LX, Sharma S, Gardner B, Escuadro B, Atianzar K, Tashkin DP, et al. IL-10 mediates sigma-1 receptor-dependent suppression of antitumor immunity. J Immunol 2003; 170: 3585-91.
110. Colabufo NA, Berardi F, Contino M, Niso M, Abate C, Perrone R, et al. Antiproliferative and cytotoxic effects of some sigma-2 agonists and sigma-1 antagonists in tumour cell lines. Naunyn Schmiedebergs Arch Pharmacol 2004; 370: 106-13.
111. Spruce BA, Campbell LA, McTavish N, Cooper MA, Appleyard MV, O'Neill M, et al. Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo. Cancer Res 2004; 64: 4875-86.
112. Vilner BJ, Bowen WD. Sigma receptor-active neuroleptics are cytotoxic to C6 glioma cells in culture. Eur J Pharmacol 1993; 244: 199-201.
113. Vilner BJ, de Costa BR, Bowen WD. Cytotoxic effects of sigma ligands: sigma receptor-mediated alterations in cellular morphology and viability. J Neurosci 1995; 15: 117-34.
114. Bowen WD, Bertha CM, Vilner BJ, Rice KC. CB-64D and CB184: ligands with high sigma 2 receptor affinity and subtype selectivity, Eur J Pharmacol 1995; 278: 257-60.
115. Crawford KW, Bowen WD. Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res 2002; 62: 313-22.
116. Vilner BJ, Bowen WD. Modulation of cellular calcium by sigma-2 receptors: release from intracellular stores in human SK-N-SH neuroblastoma cells. J Pharmacol Exp Ther 2000; 292: 900-11.
117. 2+]i in colon and mammary adenocarcinoma cells. Biochem Biophys Res Commun 1996; 219:219-26.
118. Crawford KW, Coop A, Bowen WD. Sigma-2 receptors regulate changes in sphingolipid levels in breast tumor cells. Eur J Pharmacol 2002; 443: 207-9.
119. Derocq JM, Bourrie B, Segui M, Le Fur G, Casellas P. In vivo inhibition of endotoxin-induced pro-inflammatory cytokines production by the sigma ligand SR 31747. J Pharmacol Exp Ther 1995; 272: 224-30.
120. Bourrie B, Benoit JM, Derocq JM, Esclangon M, Thomas C, Le Fur G, et al. A sigma ligand, SR 31747A, potently modulates Staphylococcal enterotoxin B-induced cytokine production in mice. Immunology 1996; 88: 389-93.
121. Labit-Le Bouteiller C, Jamme MF, David M, Silve S, Lanau C, Dhers C, et al. Antiproliferative effects of SR 31747A in animal cell lines are mediated by inhibition of cholesterol biosynthesis at the sterol isomerase step. Eur J Biochem 1998; 256: 342-9.
122. Berthois Y, Bourrie B, Galiegue S, Vidal H, Carayon P, Martin PM, et al. SR 31747A is a sigma receptor ligand exhibiting antitumoural activity both in vitro and in vivo. Br J Cancer 2003: 88: 438-46.
123. Casellas P, Galiegue S, Bourrie B, Ferrini JB, Jbilo O, Vidal H. SR 31747A: a peripheral sigma ligand with potent antitumor activities. Anticancer Drugs 2004; 15: 113-8.
124. 3H]tolyl)guanidine: a selective ligand that labels sigma-type receptors for psychotomimetic opiates and antipsychotic drugs. Proc Natl Acad Sci USA 1986; 83: 8784-8.
125. 3H]3-(3-hydroxyphenyl)-N-(l-propyl)piperidine. Proc Natl Acad Sci US. 1984; 81: 4983-7.
126. de Costa B, Radesca L, Di Paolo L, Bowen WD. Synthesis, characterization and biological evaluation of a novel class of N-(arylethyl)-N-alkyl-2-[l-pyrrolidinyl)ethylamines: structural requirements and binding affinity at the σ-receptor. J Med Chem 1992; 35: 38-47.
127. de Costa B, Radesca L, Dominguez C, Di Paolo L, Bowen WD. Synthesis and receptor binding properties of fluoro- and iodo-substituted high affinity sigma receptor ligands: identification of potential PET and SPECT sigma receptor imaging agents. J Med Chem 1992; 35: 2221-30.
128. Carroll FI, Abraham P, Parham AK, Bai X, Zhang X, Brine GA, et al. Enantiomeric N-substituted N-normetazocines: A comparative study of affinities as a σ, PCP, and μ opioid receptors. J Med Chem 1992; 35: 2812-8.
129. Gilligan JP, Cain GA, Christos TE, Cook L, Drummond S, Johnson AL, et al. Novel piperidine σ receptor ligands as potential antipsychotic drugs. J Med Chem 1992; 35: 4344-61.
130. Glennon RA, Ablordeppey SY, Ismaiel AM, El-Ashmawy MB, Fisher JB, Howie KB. Structural features important for σ1 receptor binding. J Med Chem 1994; 33: 1214-9.
131. 3H]-(+)-pentazocine-labeled (σ1) site and quantitative structure-affinity relationship studies. J Med Chem 1995, 38: 565-9.
132. Danso-Danquah R, Bai X, Zhang Y, Mascarella SW, Williams W, Sine B, et al. Synthesis and σ binding properties of 2′-substituted 5,9α-dimethyl-6,7-benzomorphans. J Med Chem 1995; 38: 2978-85.
133. Zhang Y, Williams W, Torrence-Campbell C, Bowen WD, Rice KC. Characterization of novel N,N'-disubstituted piperazines as sigma receptor ligands. J Med Chem 1998; 41: 4950-7.
134. 18F-labeled guanidines. J Med Chem 1991;34:1867-70.
135. 11C]guamidine. J Labelled Compds Radiopharm 1994; 34: 691-6.
136. 11C]-benzyl- 2′-hydroxy-5,9-dimethyl-6,7-benzomorphan). J Labelled Compds Radiopharm 1994; 34: 49-57.
137. Musachio JL, Scheffel U, Stathis M, Ravert HT, Mathews WB, Dannals RF. (+)-[C-11]-cis-N-benzyl-normetazocine: a selective ligand for sigma receptors in vivo. Life Sci 1994; 55: PL225-32.
138. 18F]fluorobenzamide: a potential ligand for PET imaging of σ receptors. Nucl Med Biol 1997; 24: 671-6.
139. 18F]fluorobenzamide: a potential ligand for PET imaging of breast cancer. Nucl Med Biol 2000; 27: 763-7.
140. 18F] labeled benzamides: high affinity sigma receptor ligands for PET imaging. Nucl Med Biol 1997: 24: 333-40.
141. 1 receptor ligands. J Med Chem 1998;41:2361-70.
142. 1251]IUDR. Nucl Med Biol 2001; 28:451-8.
143. 3H]1-(cyclopropylmethyl)-4-(2-(4-fluorophenyl)-2-oxoethyl) piperidine HBr (DuP 734). A selective ligand for sigma receptors in mouse brain in vivo. J Pharmacol Exp Ther 1993; 266: 1541-8.
144. 123I]-1-(iodopropen-2-yl)-4-[(4-cyanophenoxy) methyl]piperidine. J Med Chem 1997; 40: 1657-67.
145. 18F]-1-(3-fluoropropyl)-4-(4-cyanophenoxymethyl) piperidine: a potential sigma-1 receptor radioligands for PET. J Labelled Compds Radiopharm 1996; 38: 785-94.
146. 18F]1-(3-fluoropropyl)-4-(4-cyanophenoxymethyl) piperidine: a selective sigma-1 receptor radioligand for PET. Nucl Med Biol 1997; 24: 127-34.
147. 18F]FPS. Nucl Med Biol 2003; 30: 555-63.
148. 4-2-([3, 4-dichlorophenyl]ethyl) piperazine, a high affinity ligand for sigma receptor. J Labelled Comp Radiopharm 1993; 33: 639-43.
149. 11C]SA6298 as a PET sigmal receptor ligand. Nucl Med Biol 1999; 26: 915-22.
150. 1 receptors. Nucl Med Biol 2000; 27: 255-61.
151. 1 receptors in the cat brain. Ann Nucl Med 2000; 14: 285-92.
152. 11C]SA4503. Synapse 2001; 40:235-7.
153. Kawamura K, Kimura Y, Tsukada H, Kobayashi T, Nishiyama S, Kakiuchi T, et al. An increase of sigma receptors in the aged monkey brain. Neurobiol Aging 2003;24:745-52.
154. 1 receptors in the rat brain. Ann Nucl Med 2003;17:73-7.
155. 11C]SA4503 by P-glycoprotein modulation. Synapse 2003; 48: 80-6.
156. 18F-labeled 1-[2-(4-alkoxy-3-methoxyphenyl)ethyl]-4-(3-phenylpropyl) piperazines as sigma receptor ligands for positron emission tomography studies. Nucl Med Biol 2003;30:273-84.
157. 18F]fluoroethyl SA4503 as a PET ligand for the sigma receptor. Synapse 2002;43: 259-67.
158. 18F]fluorinated sigma receptor ligands in the conscious monkey brain. Synapse 2004;52:29-37.
159. 11C]SA4503: a feasibility study. J Nucl Med 2004;45:1939-46.
160. 18F]-BMY 14802, its enantiomers and their anatomical distributions in rodents. Nucl Med Biol 1993; 20, 625-30.
161. Ding YS, Fowler JS, Dewey SL, Wolf AP, Logan J, Gatley SJ, et al. Synthesis and PET studies of fluorine-18-BMY 14802: a potential antipsychotic drug. J Nucl Med 1993;34:246-54.
162. 11C]nemonapride to sigma receptors in the cortex and cerebellum. Nucl Med Biol 1999; 26: 627-31.
163. 11C- labelled chromeno(3,4c]pyridin-5-ones. J Labelled Compds Radiopharm. 2000; 43: 989-96.
164. 11C] methoxy-1,2,3,4-tetrahydrochromeno[3,4-c]pyridin-5-one: a PET tracer for imaging sigma receptors. Nucl Med Biol 2002; 29: 469-76.
165. 11C]NE-100 labeled in two different positions as a PET sigma receptor ligand. Nucl Med Biol 1998; 25: 195-202.
166. Marrazzo A, Prezzavento O, Pappalardo MS, Bousquet E, Iadanza M, Pike VW, et al. Synthesis of (+)- and (-)cis-2-[(1-adamantyl-amino)-methyl]-1-phenylcyclopropane derivatives as high affinity probes for sigmal and sigma2 binding sites. Farmaco 2002; 57: 45-53.
167. 125I]-1-(p-iodophenyl)-3-(1-adamantyl)guanidine, a ligand of σ binding sites. J Med Chem 1992; 35: 4683-9.
168. 125I]3′-(-)iodopentazocine, a selective σ1 receptor ligand. Eur J Pharmacol 1997; 321: 361-8.
169. He XS, Bowen WD, Lee KS, William W, Weinberger DR, de Costa BR. Synthesis and binding characteristics of potential SPECT imaging agents for sigma-1 and sigma-2 binding sites. J Med Chem 1993; 36: 566-71.
170. 125I]N-[2-(4-iodophenyl) ethyl]-N-methyl-2-(1-piperidinyl)ethylamine: a high-affinity ligand for imaging sigma receptor positive tumors. Nucl Med Biol 1996; 23: 761-6.
171. Michelot JM, Moreau MFC, Labarre PG, Madelmont JC, Veyre AJ, Papon JM, et al. Synthesis and evaluation of new iodine-125 radiopharmaceuticals as potential tracers for malignant melanoma. J Nucl Med 1991; 32:1573-80.
172. John CS, Bowen WD, Saga T, Kinuya S, Vilner BJ, Baumgold J, et al. A malignant melanoma imaging agent: Synthesis, characterization, in vitro binding and biodistribution of iodine- 125-(2-piperidinylaminoethyl)4-iodobenzamide. J Nucl Med 1993; 34, 2169-75.
173. John CS, Vilner BJ, Geyer BC, Moody T, Bowen WD. Targeting sigma receptor-binding benzamides as in vivo diagnostic and therapeutic agents for human prostate tumors. Cancer Res 1999; 59: 4578-83.
174. Zamora PO, Moody TW, John CS. Increased binding to sigma sites ofN-[1′(2-piperidinyl)ethyl]4-[I-125]-iodobenzamide (I-125-PAB) with onset of tumor cell proliferation. Life Sci 1998; 63: 1611-8.
175. 125I]MBA) for imaging breast cancer. Nucl Med Biol 1999; 26: 377-82.
176. Efange SM, Michelson RH, Knusel B, Hefti F, Boudreau RJ, Thomas JR, et al. Synthesis and biological evaluation of radioiodinated N-2-(4-piperidyl)ethyl benzamides. Nucl Med Biol 1993; 20: 527-38.
177. Michelot JM, Moreau MFC, Veyre AJ, Bonafous JF, Bacin FJ, Madelmont JC, et al. Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-N-(2-diethylaminoethyl 4-iodobenzamide). J Nucl Med 1993; 34: 1260-6.
178. 125I]-N-(N-benzylpiperidin-4-yl)-4-iodobenzamide, a new sigma receptor radiopharmaceutical: high-affinity binding to MCF-7 breast tumor cells. J Med Chem 1994; 37: 1737-9.
179. 125I]-N-(N-benzylpiperidin4-yl)-4-iodobenzamide: a high affinity sigma receptor ligand for potential imaging of breast cancer. Cancer Res 1995; 55: 3022-7.
180. 125I]Bp: a potential sigma receptor marker for human prostate tumors. Nucl Med Biol 1998; 25: 189-94.
181. 125I] iodopropen-2-yl)-4-(4-cyonophenoxymethyl)piperidine: a selective sigma receptor radioligand for SPECT. J Labelled Compds Radiopharm 1996; 38, 215-26.
182. 123I]1-(4-cyanobenzyl)-4- (trans-iodopropen-2-yl)oxy]methyl]piperidine: a novel high affinity sigma receptor radioligand for SPECT. Nucl Med Biol 1997; 24: 45-51.
183. 123I]-1-(2-hydroxyethyl)-4-(4-iodophenoxymethyl)piperidine. J Labelled Compds Radiopharm 1996; 38, 595-605.
184. Waterhouse RN, Chapman J, Izard B, Donald A, Belbin K, O'Brien JC, et al. Examination of four 123I-labeled piperidine-based sigma receptor ligands as potential melanoma imaging agents: initial studies in mouse tumor models. Nucl Med Biol 1997; 24: 587-93.
185. John CS, Lim BB, Vilner BJ, Geyer BC, Bowen WD. Substituted halogenated arylsufonamides: a new class of σ receptor binding tumor imaging agents. J Med Chem 1998; 41: 2445-50.
186. 125I](S)-trans-7-OH-PIPAT: a potential SPECT imaging agent for sigma binding sites. Life Sci 1994; 54: 593-603.
187. 99mTc-labeled sigma-receptor-binding complex: synthesis, characterization, and specific binding to human ductal breast carcinoma (T47D) cells. Bioconjug Chem 1997; 8: 304-9.
188. Choi SR, Yang B, Plossl K, Chumpradit S, Wey SP, Acton PD, et al. Development of a Tc-99m labeled sigma-2 receptor-specific ligand as a potential breast tumor imaging agent. Nucl Med Biol 2001; 28: 657-66.
189. 123-IDAB scintigraphy: clinical application in melanoma and non-small cell lung cancer. Anticancer Res 1997; 17: 1577-82.
190. Ishii K, Ishiwata K. PET imaging of sigma receptors. In: Matsuda H, Asada T Eds, Visual diagnostic imaging in dementia. Osaka, Nagai Syoten Co. 2004; 294-300 (in Japanese).
191. 2-like receptor ligands. Nucl Med Biol 2003; 30: 429-34.
192. Mach RH, Huang Y, Freeman RA, Wu L, Vangveravong S, Luedtke RR. Conformationally-flexible benzamide analogues as dopamine D3 and sigma 2 receptor ligands. Bioorg Med Chem Lett 2004; 14:195-202.
193. Gotthardt M, Boermann OC, Behr TM, Behe MP, Oyen WJ. Development and clinical application of peptide-based radiopharmaceuticals. Curr Pharm Des 2004; 10(24): 2951-63.
194. Nagy A, Schally AV. Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: a "smarter" chemotherapy. Curr Pharm Des 2005; 11 (9): 1167-80.
195. Perkins AC, Frier M. Radionuclide imaging in drug development. Curr Pharm Des 2004; 10(24): 2907-21.